RW 1 ea0207120-rw_ostherapies.htm WITHDRAWAL REQUEST

 

May 30, 2024

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

  Re: OS Therapies Incorporated
Request to Withdraw Registration Statement on Form S-1
(No. 333-271034)

 

Ladies and Gentlemen:

 

On behalf of OS Therapies Incorporated, a Delaware corporation (the “Company”), we hereby request, pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), that, effective as of the date first set forth above, the U.S. Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-271034), together with all amendments (including post-effective amendments) and exhibits thereto (collectively, the “Registration Statement”). The Registration Statement, as amended, was originally filed on March 31, 2023, declared effective by the Commission on February 14, 2024, and further amended by a post-effective amendment on May 13, 2024.

 

The Company submits this request to withdraw as, in accordance with Rule 413(a) under the Securities Act, it intends to file a new registration statement on Form S-1 relating to the Company’s contemplated initial public offering to increase the number of securities currently registered under the Registration Statement at this time.

 

The Company confirms that no securities have been, or will be, issued or sold pursuant to the Registration Statement or the public offering prospectus contained therein.

 

The Company further requests that, in accordance with Rule 457(p) of the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.

 

Should any member of the Commission’s staff have any questions concerning the enclosed materials or desire any further information or clarification in respect of this request to withdraw, please do not hesitate to contact me (tel.: (212) 451-2234) or Paul A. Romness, MPH, the Company’s Chief Executive Officer (tel.: (410) 297-7793).

 

  Very truly yours,
   
  /s/ Spencer G. Feldman
  Spencer G. Feldman

 

Enclosures

 

cc: Jimmy McNamara, Esq., SEC

Mr. Paul A. Romness, MPH
Mr. Christopher P. Acevedo